What is DXCM revenue?

DexCom Inc. (DXCM) reported $5.10B of revenue for the twelve months ended Sep 30, 2026. That is up 13.0% from the year before. Revenue for fiscal 2025 was $4.66B.

Yes. DexCom Inc. earned $991.00M in net income for the twelve months ended Sep 30, 2026, a net margin of 19.4%.

How much cash and debt does DXCM have?

DexCom Inc. reported $961.40M in cash and cash equivalents and $1.24B of debt on its most recent balance sheet in SEC filings.

How fast is DXCM revenue growing?

DexCom Inc.'s revenue changed +15.6% in fiscal 2025, to $4.66B. Its compound annual growth rate was +19.3% over 5 years and +27.8% over 10 years.

What is DXCM gross margin?

DexCom Inc.'s gross profit was $3.24B on $5.10B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 63.4%.

What is DXCM free cash flow?

DexCom Inc. generated $1.10B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.41B less capital expenditures.

What is DXCM earnings per share?

Diluted earnings per share were $2.54 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did DXCM last report financial results?

The latest statements here come from DexCom Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.

Where does this DXCM financial data come from?

Quantisnow builds these statements from the structured XBRL data DexCom Inc. files with the SEC. It is provided for information only and is not investment advice.

Financials · DXCM

DexCom Inc. (DXCM) financials

For the twelve months ended Sep 30, 2026, DexCom Inc. reported $5.10B of revenue and $991.00M of net income.

Revenue, TTM: $5.10B
Revenue growth, YoY: +13.0%
Net income, TTM: $991.00M
Net income growth, YoY: +37.5%
Net margin: 19.4%
Free cash flow, TTM: $1.10B
EPS, diluted, TTM: $2.54
EPS growth, YoY: +41.9%
Cash: $961.40M
Total debt: $1.24B
P/E: 29.88
P/S: 5.80
Market cap: $29.62B

Annual revenue$4.66B

FY2016FY2025

Annual net income$836.30M

FY2016FY2025

Annual free cash flow$1.08B

FY2016FY2025

DXCM revenue and earnings growth

DXCM revenueQ3 2026$1.34B

Quarter YoY: +11.2%
QoQ: +2.8%
FY YoY: +15.6%
5Y CAGR: +19.3%
10Y CAGR: +27.8%

DXCM revenue was $1.34B in fiscal Q3 2026 (ended Sep 30, 2026), up 11.2% from a year earlier and up 2.8% from the prior quarter. For the full fiscal 2025 it was $4.66B, up 15.6% from fiscal 2024. Compound annual growth was +19.3% over 5 years and +27.8% over 10 years. It rose in each of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

DXCM net incomeQ3 2026$275.10M

Quarter YoY: -3.1%
QoQ: +10.4%
FY YoY: +45.1%
5Y CAGR: +8.8%

DXCM net income was $275.10M in fiscal Q3 2026 (ended Sep 30, 2026), down 3.1% from a year earlier and up 10.4% from the prior quarter. For the full fiscal 2025 it was $836.30M, up 45.1% from fiscal 2024. Compound annual growth was +8.8% over 5 years. It rose in 5 of the last 6 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

DXCM EPSQ3 2026$0.72

Quarter YoY: +2.9%
QoQ: +12.5%
FY YoY: +47.2%
5Y CAGR: +9.5%

DXCM diluted EPS was $0.72 in fiscal Q3 2026 (ended Sep 30, 2026), up 2.9% from a year earlier and up 12.5% from the prior quarter. For the full fiscal 2025 it was $2.09, up 47.2% from fiscal 2024. Compound annual growth was +9.5% over 5 years.

DXCM free cash flowQ3 2026$272.70M

Quarter YoY: -52.9%
QoQ: +47.8%
FY YoY: +70.8%
5Y CAGR: +31.2%
10Y CAGR: +52.6%

DXCM free cash flow was $272.70M in fiscal Q3 2026 (ended Sep 30, 2026), down 52.9% from a year earlier and up 47.8% from the prior quarter. For the full fiscal 2025 it was $1.08B, up 70.8% from fiscal 2024. Compound annual growth was +31.2% over 5 years and +52.6% over 10 years. It rose in 8 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$4.66B	$4.03B	$3.62B	$2.91B	$2.45B	$1.93B	$1.48B	$1.03B	$718.50M	$573.30M
Cost of revenue	$1.86B	$1.59B	$1.33B	$1.03B	$768.00M	$646.60M	$544.50M	$367.70M	$226.40M	$194.90M
Gross profit	$2.80B	$2.44B	$2.29B	$1.88B	$1.68B	$1.28B	$931.50M	$663.90M	$492.10M	$378.40M
Research and development	$599.10M	$552.40M	$505.80M	$484.20M	$517.10M	$359.90M	$273.50M	$199.70M	$185.40M	$156.10M
Selling, general and admin	$1.29B	$1.29B	$1.19B	$1.01B	$810.50M	$618.20M	$515.70M	$432.80M	$349.20M	$286.20M
Operating income	$911.80M	$600.00M	$597.70M	$391.20M	$265.80M	$299.50M	$142.30M	-$186.30M	-$42.50M	-$63.90M
Interest expense	$18.30M	$19.00M	$20.30M	$18.60M	$18.80M	$17.70M	$60.30M	$22.70M	$12.80M	$700.0K
Pre-tax income	$1.09B	$709.00M	$710.40M	$390.80M	$256.80M	$297.90M	$104.20M	-$126.50M	-$48.60M	-$64.90M
Income tax	$252.10M	$132.80M	$168.90M	$49.60M	$39.90M	-$251.80M	$3.10M	$600.0K	$1.60M	$700.0K
Net income	$836.30M	$576.20M	$541.50M	$341.20M	$216.90M	$549.70M	$101.10M	-$127.10M	-$50.20M	-$65.60M
EPS, basic	$2.14	$1.46	$1.40	$0.88	$0.56	$1.46	$1.11	-$1.44	-$0.58	-$0.78
EPS, diluted	$2.09	$1.42	$1.30	$0.82	$0.53	$1.33	$1.10	-$1.44	-$0.58	-$0.78
Diluted shares	405.5M	412.7M	425.5M	427.5M	428.8M	420.4M	92.3M	88.2M	86.3M	83.6M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$917.70M	$607.30M	$566.30M	$643.30M	$1.05B	$818.20M	$446.40M	$1.14B	$441.50M	$94.50M
Receivables	$1.22B	$1.01B	$973.90M	$713.30M	$514.30M	$428.50M	$286.30M	$226.70M	$134.30M	$101.70M
Inventory	$629.10M	$542.60M	$559.60M	$306.70M	$357.30M	$234.70M	$119.80M	$70.70M	$45.20M	$45.40M
Current assets	$4.03B	$4.30B	$4.43B	$3.67B	$3.68B	$3.42B	$1.97B	$1.70B	$744.70M	$280.00M
Goodwill	$24.20M	$22.80M	$25.20M	$25.70M	$26.50M	$19.30M	$18.60M	$18.70M	$12.10M	$11.30M
Total assets	$6.34B	$6.48B	$6.26B	$5.39B	$4.93B	$4.29B	$2.40B	$1.92B	$904.10M	$402.80M
Current liabilities	$2.14B	$2.93B	$1.56B	$1.84B	$720.80M	$614.10M	$360.20M	$222.40M	$138.90M	$102.40M
Long-term debt	$1.24B	$1.24B	$2.43B	$1.20B	$1.98B	$2.03B	$1.06B	$1.01B	$327.60M	$0
Total debt	$1.24B	$1.24B	$2.43B	$1.20B	$1.98B	$2.03B	$1.06B	$1.01B	$327.60M	$0
Total liabilities	$3.59B	$4.38B	$4.20B	$3.26B	$2.89B	$2.46B	$1.51B	$1.25B	$484.70M	$119.00M
Shareholders' equity	$2.75B	$2.10B	$2.07B	$2.13B	$2.04B	$1.55B	$882.60M	$663.30M	$419.40M	$283.80M

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$1.44B	$989.50M	$748.50M	$669.50M	$442.50M	$475.60M	$314.50M	$123.20M	$92.00M	$56.20M
Capital expenditures	$363.50M	$358.80M	$236.60M	$364.80M	$389.20M	$199.00M	$180.00M	$67.10M	$66.00M	$55.70M
Free cash flow	$1.08B	$630.70M	$511.90M	$304.70M	$53.30M	$276.60M	$134.50M	$56.10M	$26.00M	$500.0K
Investing cash flow	$536.00M	-$207.50M	-$507.20M	-$521.50M	-$216.10M	-$1.02B	-$1.02B	-$139.80M	-$144.40M	-$55.90M
Financing cash flow	-$1.69B	-$734.80M	-$318.60M	-$552.50M	$10.40M	$912.10M	$10.70M	$710.40M	$399.10M	$8.10M
Share repurchases	$500.00M	$750.00M	$688.70M	$557.70M	$0	$0	$0	$100.00M	$0	$0
Stock-based compensation	$159.60M	$170.40M	$150.80M	$126.50M	$113.40M	$119.40M	$102.70M	$101.90M	$106.20M	$110.80M
Depreciation and amortization	$251.80M	$217.70M	$186.00M	$155.90M	$102.00M	$67.10M	$48.70M	$29.10M	$16.10M	$15.00M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	15.6%	11.3%	24.5%	18.8%	27.1%	30.5%	43.1%	43.6%	25.3%	42.6%
Net income growth, YoY	45.1%	6.4%	58.7%	57.3%	-60.5%	443.7%	-	-	-	-
EPS growth, YoY	47.2%	9.2%	58.5%	54.7%	-60.2%	-	-	-	-	-
Gross margin	60.1%	60.5%	63.2%	64.7%	68.6%	66.4%	63.1%	64.4%	68.5%	66.0%
Operating margin	19.6%	14.9%	16.5%	13.4%	10.9%	15.5%	9.6%	-18.1%	-5.9%	-11.1%
Net margin	17.9%	14.3%	14.9%	11.7%	8.9%	28.5%	6.8%	-12.3%	-7.0%	-11.4%
Free cash flow margin	23.1%	15.6%	14.1%	10.5%	2.2%	14.4%	9.1%	5.4%	3.6%	0.1%
Return on equity	30.5%	27.4%	26.2%	16.0%	10.6%	35.4%	11.5%	-19.2%	-12.0%	-23.1%
Return on assets	13.2%	8.9%	8.6%	6.3%	4.4%	12.8%	4.2%	-6.6%	-5.6%	-16.3%
Current ratio	1.88	1.47	2.84	1.99	5.11	5.58	5.47	7.64	5.36	2.73
Debt to equity	0.45	0.59	1.18	0.56	0.97	1.31	1.20	1.52	0.78	0.00

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$1.34B	$1.31B	$1.19B	$1.26B	$1.21B	$1.16B	$1.04B	$1.11B	$994.20M	$1.00B	$921.00M	$1.03B
Cost of revenue	$480.10M	$478.40M	$441.60M	$466.90M	$477.90M	$468.30M	$447.00M	$457.70M	$400.40M	$377.60M	$359.10M	$377.90M
Gross profit	$864.40M	$830.00M	$750.30M	$792.70M	$731.40M	$688.80M	$589.00M	$655.80M	$593.80M	$626.70M	$561.90M	$656.60M
Research and development	$161.60M	$153.00M	$145.30M	$148.20M	$157.50M	$148.20M	$145.20M	$139.50M	$135.40M	$136.00M	$141.50M	$136.10M
Selling, general and admin	$375.60M	$358.70M	$349.70M	$321.50M	$331.40M	$328.00M	$310.10M	$327.40M	$306.40M	$332.70M	$319.30M	$303.60M
Operating income	$327.20M	$318.30M	$255.30M	$323.00M	$242.50M	$212.60M	$133.70M	$188.90M	$152.00M	$158.00M	$101.10M	$216.90M
Interest expense	$3.10M	$3.00M	$3.10M	$4.20M	$4.70M	$4.70M	$4.70M	$4.90M	$4.70M	$4.80M	$4.60M	$4.90M
Pre-tax income	$334.70M	$317.50M	$269.50M	$340.70M	$352.30M	$241.10M	$154.30M	$211.30M	$177.40M	$187.80M	$132.50M	$246.20M
Income tax	$59.60M	$68.40M	$70.00M	$73.40M	$68.50M	$61.30M	$48.90M	$59.60M	$42.80M	$44.30M	-$13.90M	-$10.10M
Net income	$275.10M	$249.10M	$199.50M	$267.30M	$283.80M	$179.80M	$105.40M	$151.70M	$134.60M	$143.50M	$146.40M	$256.30M
EPS, basic	$0.73	$0.65	$0.52	$0.68	$0.73	$0.46	$0.27	$0.38	$0.34	$0.36	$0.38	$0.66
EPS, diluted	$0.72	$0.64	$0.51	$0.67	$0.70	$0.45	$0.27	$0.37	$0.34	$0.35	$0.36	$0.61
Diluted shares	383.5M	390.1M	393.6M	-	407.4M	408.2M	407.5M	-	410.2M	416.8M	416.7M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$961.40M	$1.10B	$1.12B	$917.70M	$1.84B	$1.16B	$904.90M	$607.30M	$621.20M	$939.20M	$851.20M	$566.30M
Receivables	$1.19B	$1.26B	$1.09B	$1.22B	$1.11B	$1.35B	$1.16B	$1.01B	$1.00B	$945.20M	$978.60M	$973.90M
Inventory	$770.70M	$726.40M	$693.60M	$629.10M	$604.10M	$570.70M	$538.20M	$542.60M	$586.30M	$570.30M	$589.10M	$559.60M
Current assets	$3.92B	$4.09B	$4.33B	$4.03B	$5.22B	$5.03B	$4.55B	$4.30B	$4.26B	$4.85B	$4.62B	$4.43B
Goodwill	$24.00M	$24.10M	$24.20M	$24.20M	$24.10M	$24.10M	$23.10M	$22.80M	$23.80M	$23.30M	$23.20M	$25.20M
Total assets	$6.24B	$6.46B	$6.63B	$6.34B	$7.50B	$7.33B	$6.75B	$6.48B	$6.35B	$6.80B	$6.48B	$6.26B
Current liabilities	$2.25B	$2.36B	$2.22B	$2.14B	$3.34B	$3.31B	$3.04B	$2.93B	$1.73B	$1.72B	$1.59B	$1.56B
Long-term debt	$1.24B	$1.24B	$1.24B	$1.24B	$1.24B	$1.24B	$1.24B	$1.24B	$2.44B	$2.44B	$2.44B	$2.43B
Total debt	$1.24B	$1.24B	$1.24B	$1.24B	$1.24B	$1.24B	$1.24B	$1.24B	$2.44B	$2.44B	$2.44B	$2.43B
Total liabilities	$3.70B	$3.83B	$3.68B	$3.59B	$4.77B	$4.75B	$4.49B	$4.38B	$4.37B	$4.36B	$4.24B	$4.20B
Shareholders' equity	$2.54B	$2.62B	$2.96B	$2.75B	$2.73B	$2.57B	$2.27B	$2.10B	$1.98B	$2.43B	$2.25B	$2.07B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$325.60M	$269.20M	$525.60M	$294.00M	$659.90M	$303.00M	$183.80M	$301.40M	$199.50M	$279.40M	$209.20M	$133.60M
Capital expenditures	$52.90M	$84.70M	$76.60M	$101.90M	$80.50M	$94.10M	$87.00M	$124.60M	$111.20M	$66.10M	$56.90M	$52.50M
Free cash flow	$272.70M	$184.50M	$449.00M	$192.10M	$579.40M	$208.90M	$96.80M	$176.80M	$88.30M	$213.30M	$152.30M	$81.10M
Investing cash flow	-$76.70M	$329.80M	-$298.50M	$306.60M	$192.80M	-$63.60M	$100.20M	-$303.70M	$210.30M	-$188.90M	$74.80M	$414.90M
Financing cash flow	-$391.50M	-$607.30M	-$25.00M	-$1.52B	-$175.00M	-$1.70M	$12.50M	-$1.60M	-$736.50M	-$1.40M	$4.70M	-$631.90M
Share repurchases	$400.00M	-	-	$312.80M	$187.20M	-	-	$0	$750.00M	-	-	$500.00M
Stock-based compensation	$36.80M	$39.00M	$43.30M	$35.00M	$45.10M	$45.30M	$34.20M	$43.30M	$43.40M	$44.70M	$39.00M	$36.90M
Depreciation and amortization	$74.50M	$68.20M	$67.10M	$65.20M	$63.60M	$63.00M	$60.00M	$57.80M	$55.30M	$52.10M	$52.50M	$52.50M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	11.2%	13.1%	15.0%	13.1%	21.6%	15.2%	12.5%	7.6%	2.0%	15.3%	24.2%	26.9%
Net income growth, YoY	-3.1%	38.5%	89.3%	76.2%	110.8%	25.3%	-28.0%	-40.8%	11.5%	23.8%	201.2%	179.2%
EPS growth, YoY	2.9%	42.2%	88.9%	81.1%	105.9%	28.6%	-25.0%	-39.3%	17.2%	25.0%	200.0%	165.2%
Gross margin	64.3%	63.4%	62.9%	62.9%	60.5%	59.5%	56.9%	58.9%	59.7%	62.4%	61.0%	63.5%
Operating margin	24.3%	24.3%	21.4%	25.6%	20.1%	18.4%	12.9%	17.0%	15.3%	15.7%	11.0%	21.0%
Net margin	20.5%	19.0%	16.7%	21.2%	23.5%	15.5%	10.2%	13.6%	13.5%	14.3%	15.9%	24.8%
Free cash flow margin	20.3%	14.1%	37.7%	15.3%	47.9%	18.1%	9.3%	15.9%	8.9%	21.2%	16.5%	7.8%
Current ratio	1.74	1.73	1.95	1.88	1.56	1.52	1.50	1.47	2.46	2.82	2.90	2.84
Debt to equity	0.49	0.47	0.42	0.45	0.45	0.48	0.55	0.59	1.23	1.00	1.08	1.18

Source: XBRL data DexCom Inc. files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

DXCM peers

Company	Revenue	Growth	Net income	Net margin	Market cap
DXCM	$5.10B	+13.0%	$991.00M	19.4%	$29.62B
SYKStryker Corporation	$26.30B	+7.9%	$3.62B	13.8%	$124.05B
MMM3M Company	$25.25B	+1.7%	$3.54B	14.0%	$95.67B
BSXBoston Scientific Corporation	$21.07B	+8.9%	$3.50B	16.6%	$61.96B
BDXBecton Dickinson and Company	$23.25B	+17.4%	$941.00M	4.0%	$57.71B
MDLNMedline Inc.	$30.68B	-	$683.00M	2.2%	$52.13B
RMDResMed Inc.	$5.73B	+9.0%	$1.59B	27.8%	$33.10B
WSTWest Pharmaceutical Services Inc.	$3.40B	+12.6%	$638.90M	18.8%	$27.85B
SOLVSolventum Corporation	$8.16B	-2.8%	$156.00M	1.9%	$15.38B

DXCM FAQ

9 questions

What is DXCM revenue?
DexCom Inc. (DXCM) reported $5.10B of revenue for the twelve months ended Sep 30, 2026. That is up 13.0% from the year before. Revenue for fiscal 2025 was $4.66B.
Is DXCM profitable?
Yes. DexCom Inc. earned $991.00M in net income for the twelve months ended Sep 30, 2026, a net margin of 19.4%.
How much cash and debt does DXCM have?
DexCom Inc. reported $961.40M in cash and cash equivalents and $1.24B of debt on its most recent balance sheet in SEC filings.
How fast is DXCM revenue growing?
DexCom Inc.'s revenue changed +15.6% in fiscal 2025, to $4.66B. Its compound annual growth rate was +19.3% over 5 years and +27.8% over 10 years.
What is DXCM gross margin?
DexCom Inc.'s gross profit was $3.24B on $5.10B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 63.4%.
What is DXCM free cash flow?
DexCom Inc. generated $1.10B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.41B less capital expenditures.
What is DXCM earnings per share?
Diluted earnings per share were $2.54 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did DXCM last report financial results?
The latest statements here come from DexCom Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.
Where does this DXCM financial data come from?
Quantisnow builds these statements from the structured XBRL data DexCom Inc. files with the SEC. It is provided for information only and is not investment advice.